Combination Regimens of Mirvetuximab Soravtansine, A Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, With Standard-Of-Care Agents Offer Promise for the Treatment of Ovarian Cancer

Todd M Bauer*
Sarah Cannon Research Institute, USA

In a recent issue of Neoplasia, Ponte et al demonstrated the capacity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), to augment the in vitro and in vivo activity of approved chemotherapeutic and biologic agents used in the management of ovarian cancer [1]. These preclinical findings provide a rationale for the further investigation of the antitumor activity of IMGN853 in this malignancy, particularly as part of novel combinatorial strategies with established therapeutic regimens. Current standard-of-care treatment for ovarian cancer, the most lethal gynecologic malignancy, involves debulking surgery typically followed by platinum-based combination chemotherapy [2]. This strategy has changed little in more than a decade and the only marginal improvements seen in terms of survival for this disease over this time underscore the urgent need for new agents and approaches to improve outcomes. An increased understanding of the biological complexity of ovarian tumors has prompted the exploration of targeted strategies designed to shift treatment away from broad-based cytotoxic use towards more tailored interventions [3].

One validated modality involves combining targeted agents, which possess distinct mechanisms of action and favorable tolerability, with established chemotherapeutics-as exemplified by the approval of bevacizumab for use alongside conventional cytotoxic drugs in platinum-resistant, recurrent epithelial ovarian cancer (EOC) [4]. FRα is a cell surface transmembrane glycoprotein that facilitates the unidirectional transport of folates into cells. In normal tissues, receptor expression is restricted to a variety of polarized epithelia - however, aberrant high FRα expression is characteristic of a number of solid tumors, including EOC [5]. This differential distribution pattern has made FRα an attractive candidate for the development of novel, targeted therapeutics. Early approaches to targeting the folate receptor included evaluation of a humanized anti-FRα monoclonal antibody, farletuzumab, to determine whether it would exert clinically relevant antitumor activity through antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity [6].

In addition, two small molecule folate-cytotoxic agent conjugates, BMS-748285 and vintafolide, have been examined as a means of selectively delivering cytotoxic compounds directly to cancer cells with high folate receptor expression [6]. Although well tolerated in human studies, the clinical development of these agents was limited by a lack of meaningful efficacy in pivotal trials, either as single agents or as part of combination regimens [7,8]. The differential expression of FRα and its ability to internalize large molecules makes this receptor well suited for the unidirectional transport of folates into cells. In normal tissues, receptor expression is restricted to a variety of polarized epithelia - however, aberrant high FRα expression is characteristic of a number of solid tumors, including EOC [5]. This differential distribution pattern has made FRα an attractive candidate for the development of novel, targeted therapeutics. Early approaches to targeting the folate receptor included evaluation of a humanized anti-FRα monoclonal antibody, farletuzumab, to determine whether it would exert clinically relevant antitumor activity through antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity [6].

The ADC used in the study, mirvetuximab soravtansine (IMGN853), consists of a humanized FRα-binding monoclonal antibody conjugated to the maytansinoid DM4 [10]. IMGN853 binds with high affinity and specificity to FRα on the surface of tumor cells which, upon antigen binding, promotes ADC internalization and intracellular release of DM4. DM4 subsequently acts as an anti-mitotic agent to inhibit tubulin polymerization and disrupt microtubule assembly, resulting in cell cycle arrest and apoptosis [11]. In early clinical testing, IMGN853 has shown a manageable safety profile and encouraging signs of single-agent activity, particularly in patients with advanced EOC [12]. In an attempt to inform the continued development of IMGN853 as a targeted therapeutic, the authors assessed the combinatorial activity of IMGN853 with a variety of clinically relevant agents in preclinical models of ovarian cancer. They showed that co-treatment of IMGN853 with conventional therapies used in both the front-line (carboplatin) and recurrent settings (pegylated liposomal doxorubicin; PLD) resulted in synergistic anti-proliferative effects in vitro and significantly improved antitumor activity in vivo, including superior efficacy in patient-derived xenograft tumors. Moreover, a noteworthy finding of the study was the markedly improved activity afforded by the combination of IMGN853 and bevacizumab, which caused significant tumor regressions and complete responses in mice bearing platinum-resistant EOC tumors. The mechanism by which IMGN853 achieved improved therapeutic indices in combination with bevacizumab is still under investigation, however it is important to note that in the pivotal studies that led to the approval of bevacizumab for ovarian cancer treatment, efficacy was demonstrated only with regard to progression-free survival, with less reliable effects seen on overall survival - a pattern repeated in more recent clinical evaluations of other anti-angiogenic agents [13].

Thus, it appears that an opportunity exists to improve the efficacy of antiangiogenic therapy in this disease, and it is reasonable to suggest that tailored treatment strategies with optimized combinatorial partners (such as IMGN853) are an area of considerable translational interest. Overall, the demonstrations of combinatorial benefit conferred by the addition of the first FRα-targeting ADC to established therapies provides a compelling framework for the potential application of IMGN853 in the future management of ovarian cancer. In this regard, the ongoing phase Ib trial study in FRα-positive, advanced EOC patients (FORWARD II; NCT02606305) evaluating the safety and efficacy of the ADC alongside bevacizumab, carboplatin, PLD, or pembrolizumab is...
warranted. The results of that trial will be informative in determining the feasibility of integrating IMGN853 into novel ovarian cancer treatments and for realizing the full potential of FRα-targeting as a strategy for improving outcomes for patients with this disease.

References


8. Merck and Endocyte announce independent DSMB recommends Vintafolide PROCEED Phase 3 trial be stopped for futility following interim analysis.


